A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced ...
Mirum Pharmaceuticals, Inc. today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 ...
The search strategy was developed by a medical librarian combining the terms false positive results, urine, and substance abuse testing and the generic names of 116 medications. When possible ...
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...
Cycle Pharmaceuticals, Inc. (Cycle) announces today completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM® (monomethyl fumarate) product for the treatment of ...